BACKGROUND: The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes. METHODS: We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2 , and triple negative. RESULTS: Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P < .001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P < .001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%). CONCLUSIONS: Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.
BACKGROUND: The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes. METHODS: We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2 , and triple negative. RESULTS: Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P < .001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P < .001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%). CONCLUSIONS: Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.
Authors: Meena S Moran; Stuart J Schnitt; Armando E Giuliano; Jay R Harris; Seema A Khan; Janet Horton; Suzanne Klimberg; Mariana Chavez-MacGregor; Gary Freedman; Nehmat Houssami; Peggy L Johnson; Monica Morrow Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: André Hennigs; Fabian Riedel; Adam Gondos; Peter Sinn; Peter Schirmacher; Frederik Marmé; Dirk Jäger; Hans-Ulrich Kauczor; Anne Stieber; Katja Lindel; Jürgen Debus; Michael Golatta; Florian Schütz; Christof Sohn; Jörg Heil; Andreas Schneeweiss Journal: BMC Cancer Date: 2016-09-15 Impact factor: 4.430
Authors: Petr Lapcik; Anna Pospisilova; Lucia Janacova; Peter Grell; Pavel Fabian; Pavel Bouchal Journal: Cancers (Basel) Date: 2020-09-16 Impact factor: 6.639
Authors: Isaac Kim; Hee Jun Choi; Jai Min Ryu; Se Kyung Lee; Jong Han Yu; Seok Won Kim; Seok Jin Nam; Jeong Eon Lee Journal: J Breast Cancer Date: 2018-06-20 Impact factor: 3.588